- Home
- BLBX vs AIM Comparison
BLBX vs AIM Comparison
Compare BLBX & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLBX
- AIM
- Stock Information
- Founded
- BLBX 2014
- AIM 1966
- Country
- BLBX United States
- AIM United States
- Employees
- BLBX N/A
- AIM N/A
- Industry
- BLBX EDP Services
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLBX Technology
- AIM Health Care
- Exchange
- BLBX Nasdaq
- AIM Nasdaq
- Market Cap
- BLBX 10.6M
- AIM 8.8M
- IPO Year
- BLBX N/A
- AIM N/A
- Fundamental
- Price
- BLBX $3.02
- AIM $0.09
- Analyst Decision
- BLBX
- AIM Strong Buy
- Analyst Count
- BLBX 0
- AIM 2
- Target Price
- BLBX N/A
- AIM $2.75
- AVG Volume (30 Days)
- BLBX 243.7K
- AIM 410.1K
- Earning Date
- BLBX 05-14-2025
- AIM 03-27-2025
- Dividend Yield
- BLBX N/A
- AIM N/A
- EPS Growth
- BLBX N/A
- AIM N/A
- EPS
- BLBX N/A
- AIM N/A
- Revenue
- BLBX $2,566,946.00
- AIM $170,000.00
- Revenue This Year
- BLBX N/A
- AIM N/A
- Revenue Next Year
- BLBX N/A
- AIM $1,693.10
- P/E Ratio
- BLBX N/A
- AIM N/A
- Revenue Growth
- BLBX N/A
- AIM N/A
- 52 Week Low
- BLBX $1.51
- AIM $0.11
- 52 Week High
- BLBX $6.00
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- BLBX 47.09
- AIM 34.03
- Support Level
- BLBX $3.07
- AIM $0.11
- Resistance Level
- BLBX $3.84
- AIM $0.16
- Average True Range (ATR)
- BLBX 0.42
- AIM 0.01
- MACD
- BLBX -0.04
- AIM -0.00
- Stochastic Oscillator
- BLBX 21.15
- AIM 0.00
About BLBX Blackboxstocks Inc.
Blackboxstocks Inc is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Its web-based software (the Blackbox System) employs predictive technology enhanced by artificial intelligence to find volatility and unusual market activity that may result in a rapid change in the price of a stock or option. It provides users with a fully interactive social media platform that is integrated into its dashboard, enabling users to exchange information and ideas quickly and efficiently through a common network. The company introduced a live audio/video feature that allows members to broadcast on their channels to share trading strategies and market insight within the Blackbox community.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.